A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer

Abramson, Vandana G ; Oliveira, Mafalda ; Cervantes, Andres ; Wildiers, Hans ; Patel, Manish R ; Bauer, Todd M ; Bedard, Philippe L ; Becerra, Carlos ; Richey, Stephen ; Wei, Michael C ; Reyner, Eric ; Bond, John ; Cui, Na ; Wilson, Timothy R ; Moore, Heather M ; Saura, Cristina ; Krop, Ian E

BREAST CANCER RESEARCH AND TREATMENT, 2019-11, Vol.178 (1), p.121-133 [Periódico revisado por pares]

SPRINGER

Texto completo disponível